Tempus raises FY2026 revenue outlook; Personalis adds execution and financing risk

Transcript intelligence

What changed

Compared with the prior quarter’s analysis, Tempus reported 22% year-over-year revenue growth, raised its FY2026 revenue range to $1.595–$1.605 billion from $1.59–$1.60 billion, and added the announced Personalis acquisition to its plan to expand MRD testing. The quarter also included FDA approval for xT CDx; xF clearance remains pending.

Guidance delta

Raised FY2026 revenue guidance to $1.595–$1.605 billion, versus the prior-quarter range of $1.59–$1.60 billion. The supplied analysis does not report a change to adjusted EBITDA guidance this quarter.

Key takeaways

• Revenue increased 22% year over year to $382.5 million, with diagnostics up 20% and data applications up 28%.
• Management raised FY2026 revenue guidance to $1.595–$1.605 billion, describing roughly 25% growth.
• The xT CDx tumor-only assay received FDA approval; clearance for the xF liquid biopsy remains pending.
• The planned Personalis acquisition is intended to expand MRD testing, while adding integration and financing considerations.

Management priorities

• Pursue additional long-term pharma data-licensing agreements and adoption of the Lens foundation-model platform.
• Advance xF liquid-biopsy clearance and build on xT CDx approval and associated pricing opportunities.
• Expand MRD testing and sales capacity following the planned Personalis transaction.
• Develop the next foundation-model version and fund the acquisition while limiting dilution, as described in the analysis.